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Abstract
The lipophilic cationic compound quinacrine has been used as an antimalarial drug for over 75 years but its
pharmacokinetic profile is limited. Here, we report on the pharmacokinetic properties of quinacrine in mice. Following an
oral dose of 40 mg/kg/day for 30 days, quinacrine concentration in the brain of wild-type mice was maintained at a
concentration of ,1 mM. As a substrate of the P-glycoprotein (P-gp) efflux transporter, quinacrine is actively exported from
the brain, preventing its accumulation to levels that may show efficacy in some disease models. In the brains of P-gp–
deficient Mdr1
0/0 mice, we found quinacrine reached concentrations of ,80 mM without any signs of acute toxicity.
Additionally, we examined the distribution and metabolism of quinacrine in the wild-type and Mdr1
0/0 brains. In wild-type
mice, the co-administration of cyclosporin A, a known P-gp inhibitor, resulted in a 6-fold increase in the accumulation of
quinacrine in the brain. Our findings argue that the inhibition of the P-gp efflux transporter should improve the poor
pharmacokinetic properties of quinacrine in the CNS.
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Introduction
In the search for inhibitors of PrP
Sc formation, we and others
found that phenothiazines and acridines like quinacrine lowered
the levels of PrP
Sc in scrapie-infected neuroblastoma (ScN2a) cells
[1,2]. Those findings suggested the possibility that quinacrine
might be an effective therapeutic for the uniformly fatal
neurodegenerative disorder Creutzfeldt-Jakob disease (CJD) in
humans. Disappointingly, quinacrine was ineffective in treating
prion disease in humans and experimental animals [3,4,5]. The
effective doses of quinacrine reducing PrP
Sc by 50% in cell cultures
were reported to be ,1 mM and ,7 mM extracellularly and
intracellularly, respectively [2,6]. Puzzled by the lack of therapeu-
tic efficacy, we examined the pharmacokinetic properties of
quinacrine in mice.
Quinacrine is an acridine-based compound that was first
synthesized in 1931 (Bayer, Germany) and initially used for the
prophylaxis and treatment of malaria. Quinacrine has also been
used to treat giardiasis, systemic lupus erythematosis and
rheumatoid arthritis [7,8]; it has also found utility as an
anthelmintic [7] and female sterilization in a few countries [9].
Quinacrine also works against cutaneous leishmaniasis and
Trypanosoma cruzi in vitro [10,11]. As a nonselective inhibitor of
phospholipase A2, quinacrine has thus been suggested as a
possible therapeutic for neoplasms and heat-induced injury
[12,13]. Results from another in-vitro study suggested that
quinacrine may be a potent compound for treating glioblastomas
by inducing autophagic vacuoles leading to tumor cell death [14].
Quinacrine has been reported to stabilize p53, induce the
upregulation of downstream pro-apoptotic molecules, and induce
p53-dependent tumor cell death [15].
The delivery of quinacrine to the mouse brain is complicated
by its rapid efflux via the P-glycoprotein (P-gp) transporter found
in endothelial cells of the central nervous system (CNS)
[16,17,18]. The P-gp transporter is well-studied in neoplastic
cells and in the blood-brain barrier (BBB) [19,20,21,22]. P-gp
actively transports quinacrine across the BBB, inhibiting its
accumulation and maintaining its concentration at ,1 mM in the
brain [23]. Therefore, the bioavailability and efficacy of
quinacrine may be reduced when administered in vivo compared
to effective concentrations determined in vitro. In this paper, we
report on the pharmacokinetics of quinacrine in wild-type (wt)
and Mdr1
0/0 mice in which the mdr1a and mdr1b genes encoding
the P-gp transporters were ablated [24]. We established an oral
administration protocol that maximized the accumulation of
quinacrine, up to 200 mM, in the brains of Mdr1
0/0 mice without
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e39112signs of toxicity. We also determined the half-life (t1/2)o f
quinacrine in the brains, spleens, kidneys, and livers of wt and
Mdr1
0/0 mice. Using the intrinsic fluorescence of quinacrine, we
were able to observe the anatomic distribution of quinacrine in
the brains of quinacrine-treated mice. To increase the concen-
tration of quinacrine in the brains of wt mice, we administered
the P-gp inhibitor cyclosporine A (CyA), which produced a 6-fold
increase in brain quinacrine levels.
Materials and Methods
Ethics Statement
All protocols involving animal studies were approved by the
University of California San Francisco Animal Care and Use
Committee (AN076161-02).
Materials
Quinacrine dihydrochloride, acetonitrile, methanol, quinidine,
CyA, verapamil, and disulfiram were purchased from Sigma-
Aldrich (St. Louis, MO).
Animals and Tissue Preparation
Approximately five-week-old male and female wt FVB and
Mdr1
0/0 mice were purchased from Charles River (Wilmington,
MA) and Taconic (Germantown, NY), respectively. For the orally
treated group, mice were fed with 40 mg/kg/day of quinacrine in
a chocolate-flavored liquid diet [25]. After treatment, mice (n=3)
were euthanized at various time points, and brain, spleen, liver,
and kidney tissues were collected and flash frozen. Tissue
homogenates (10% w/v) were prepared using a Precellys 24
homogenizer (Bertin Technologies, Montigny-le-Bretonneux,
France) in pure distilled water (Invitrogen, San Diego, CA),
aliquoted, and stored at 280uC.
P-gp Inhibitor Study
P-gp inhibitor stock solutions of quinidine, CyA, verapamil,
or disulfiram, were prepared in PBS or DMSO. The solutions
were diluted to 100 mg/kg with PBS, based on 25 g of mouse
body weight and the final injection volume of 200 ml per mouse.
The P-gp inhibitor solution was administered to FVB mice
(n=4) by gavage. After 1 or 2 h of P-gp inhibitor administra-
tion, 10 mg/kg of quinacrine in PBS was given to FVB mice
via gavage. As controls, Mdr1
0/0 mice were also treated with
10 mg/kg quinacrine in PBS via gavage. Mice were euthanized
at 6 or 12 h post-quinacrine administration, and tissues were
collected and flash frozen. Tissue homogenates (10% w/v) were
prepared as described as above and 200-ml aliquots were stored
at 280uC.
Quinacrine Extraction
Preparation of standard solutions. Working solutions
containing quinacrine, O-demethyl-quinacrine (M1), and mono-
desethyl-quinacrine (M2) (10 mg/ml each) were prepared in 50%
acetonitrile solution. Working solution was diluted with untreated,
control 10% tissue homogenates to make 500 mlo f1mg/ml of
standard 1 solution for each tissue type. The standard 1 solution
was then serially diluted two-fold. Nine standard solutions (200 ml
each) including a blank solution (0 mg/ml) were frozen at 280uC.
Extraction. A total of 400 ml of acetonitrile containing the internal
standard (50 ng/ml of chlorophenamine) was added to 200 mlo f
10% tissue homogenates or standard solutions. The samples were
vortexed vigorously twice for 1 min and centrifuged at 16,000 g
for 5 min.
LC/MS/MS
Concentrations of quinacrine and metabolites M1 and M2 were
measured by LC/MS/MS as described previously [18]. Briefly,
the LC/MS/MS system consisted of Shimadzu LC-10 AD pumps,
a Waters Intelligent Sample Processor 717 Plus autosampler, and a
Micromass Quattro LC Ultima triple quadruple tandem mass
spectrometer. The mass spectrometer was set to electrospray
ionization in the positive-ion mode. Quinacrine, M1, and M2
were monitored by multiple reaction monitoring (MRM) at
400.5.142.2 m/z for quinacrine, 384.5.142.2 m/z for M1,
372.2.114.2 m/z for M2, and 277.2.142.2 m/z for internal
standard (chlorphenamine). The column was a Betasil C18
column (5064.6 mm) from Hypersil-Keystone and the mobile
phase consisted of CH3OH/H2O/trifluoroacetic acid (45:55:0.05)
with 1 mM ammonium formate. The flow rate was 0.8 ml/min.
Fluorescence Microscopy
Wild-type and Mdr1
0/0 mice were treated with 20 mg/kg of
quinacrine via intravenous (IV) tail injection or 40 mg/kg/day of
quinacrine in a chocolate-flavored liquid diet. At 1 and 24 h after
quinacrine treatment, IV-injected mice were euthanized by CO2
asphyxiation and the cervical spine transected just below the skull.
The brains were removed and snap frozen on powdered dry ice.
Half of each brain was used for cryosectioning, and the other half
for measurement of quinacrine concentrations. Frozen half-brains
were mounted on a freezing stage using Cryo-gel (Instrumedics, St.
Louis, MO) with the cerebellum facing out. Frozen coronal
sections of 8 mm were cut at 222uC using a Microm HM 505E
cryostat and mounted on Fisher Superfrost Plus slides. Serial
sections were used for quinacrine and nuclear (49,6-diamidino-2-
phenylindole (DAPI), Vector Laboratories, Burlingame, CA)
imaging. For quinacrine, frozen sections stored at 280uC were
air-dried at room temperature (RT) for 10 min, mounted with
100 ml glycerin (Fisher, Hudson, NH), coverslipped, and sealed.
When not on the microscope stage, slides were kept in a dark box
on wet ice to slow disbursement of quinacrine in the tissue. All
images were taken immediately after mounting using an inverted
Leica DM IRB microscope through a FITC (fluorescein isothio-
cyanate) filter using a SpotFlex camera and Spot advanced
software on the FITC setting. For DAPI, serial sections adjacent to
those used for quinacrine imaging were air-dried at RT for 20 min
and post-fixed in 4% formaldehyde (PolySciences Ultrapure EM
grade, Warrinton, PA) in PBS for 15 min at RT, rinsed in PBS,
mounted with Vectashield Mounting Media with DAPI, and
imaged as described above, but using the DAPI filter and settings.
Images were taken from the brainstem immediately adjacent to
the most posterior portion of the cerebellum (Bregma 27.70 mm
Table 1. Quinacrine concentration (mM) in wild-type and
Mdr1
0/0 mice.
Tissue Wild-type Mdr1
0/0 P value
Brain 1.660.3 8462.4 0.0003
Kidney 55617 138633 0.01
Liver 207625 223650 0.7
Spleen 9765.3 154616 0.02
Wild-type and Mdr1
0/0 mice (n=3) were treated with 40 mg/kg/day of
quinacrine in a chocolate-flavored liquid diet for 29 d. After treatment, the mice
were euthanized and the quinacrine concentration in each tissue was measured
by LC/MS/MS. Values are expressed as the mean 6 standard deviation (SD).
doi:10.1371/journal.pone.0039112.t001
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granule cell layer and molecular cell layer in Crus II lobuli
ansiformis and of the white matter track in the lobulus simplex
midway through the cerebellum (Bregma 27.32 mm), of layer IV
in the cortex immediately above the dentate gyrus, the dentate
gyrus, and the thalamus immediately below the dentate gyrus
(Bregma 22.212 mm). Image files generated on the Spot program
were later processed in Adobe Photoshop for publication images.
Results
Accumulation of Quinacrine in the Brains of Mdr1
0/0 Mice
In earlier studies, we compared the levels of quinacrine in the
brains of wt and Mdr1
0/0 mice after oral gavage or IV injections
[18]. To study the therapeutic efficacy of quinacrine, we
developed a chocolate-flavored liquid diet, in which quinacrine
was dissolved [25]. In initial dosing experiments, we found that
40 mg/kg/day was the maximum tolerable and nontoxic dose.
After feeding 40 mg/kg/day of quinacrine in a chocolate-flavored
liquid diet for 29 days, quinacrine levels in brain, kidney, spleen,
and liver tissues were measured by LC/MS/MS (Table 1). In the
brains of wt and Mdr1
0/0 mice, the quinacrine concentrations were
1.6 mM and 84 mM, respectively (Table 1). The quinacrine
concentration in the brains of wt mice was consistent with
previously reported data [26]. Mdr1
0/0 mice showed higher
quinacrine accumulation in the spleen and kidney than wt mice
while the quinacrine concentration was similar in the liver for both
wt and Mdr1
0/0 mice (Table 1).
Next, we examined the quinacrine accumulation during long-
term treatment. We treated Mdr1
0/0 mice with 40 mg/kg/day
of quinacrine continuously for up to 250 d. Remarkably,
quinacrine concentrations reached approximately 200, 250,
300, and 500 mM in the brain, kidney, spleen, and liver,
respectively, with only minimal signs of toxicity (Figure 1).I n
addition to discoloration of hair and/or skin, Mdr1
0/0 mice
Figure 1. Quinacrine accumulation in brain (circles), spleen
(triangles), liver (squares), and kidney (diamonds) tissues of
Mdr1
0/0 mice. Mdr1
0/0 mice were treated with 40 mg/kg/day of
quinacrine in a chocolate-flavored liquid diet continuously for up to
250 d. Mice were euthanized at the time-points indicated and the
quinacrine concentration in each tissue was measured by LC/MS/MS.
Data points are the mean concentrations (n=3) and the error bars
represent SD.
doi:10.1371/journal.pone.0039112.g001
Figure 2. Steady-state concentrations of quinacrine and its
metabolites in wt and Mdr1
0/0 mouse brains. Mice were treated
with 40 mg/kg/day of quinacrine in a chocolate-flavored liquid diet for
31 d and then euthanized. The quinacrine concentration in the brain
was measured by LC/MS/MS. Bars represent represent the mean
concentration (n=3); error bars represent SD. Y-axis shown in
logarithmic scale. M1 metabolite levels for wild-type mice were under
the detection limit.
doi:10.1371/journal.pone.0039112.g002
Figure 3. Clearance of quinacrine and its metabolites in wt
(filled symbols) and Mdr1
0/0 (open symbols) mouse brains. Mice
were treated with 40 mg/kg/day of quinacrine in a chocolate-flavored
liquid diet for 31 d and then euthanized. The quinacrine concentration
in the brain was measured by LC/MS/MS. Each data point represents the
mean concentration (n=3); error bars represent SD. Y-axis shown in
logarithmic scale. Circles, quinacrine; diamonds, M1; squares, M2.
Metabolite M1 levels for wt mice were under the detection limit.
doi:10.1371/journal.pone.0039112.g003
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reduced locomotor activity. Quinacrine concentrations in all
four tissues rapidly increased after a few days of treatment and
continued to increase gradually up to 250 d (Figure 1).N o
quinacrine-induced neuropathology was observed in comparison
to age-matched untreated brains. Mild focal necrosis and
macrophage clusters were found in the livers of both treated
and untreated mice (data not shown).
Clearance of Quinacrine from the Brains of Mdr1
0/0 Mice
During the course of quinacrine exposure, the drug was
metabolized by the processes of O-demethylation and N-desethyla-
tion to yield metabolites, O-demethyl-quinacrine (M1) and mono-
desethyl-quinacrine (M2), respectively [18]. To examine the
metabolism of quinacrine in the brain, we measured the
concentrations of quinacrine and its metabolites in both wt and
Mdr1
0/0 mice. Both wt and Mdr1
0/0 mice were treated with
40 mg/kg/day of quinacrine for 31 days. Tissues were collected at
various time points after halting treatment and concentrations of
quinacrine, M1, and M2 were measured by LC/MS/MS.
At the end of the treatment period, quinacrine and its
metabolites (M1 and M2) achieved steady-state brain concentra-
tions in both wt and Mdr1
0/0 mice. The concentration of M2, the
major metabolite of quinacrine, was less than 25% of the
quinacrine concentration in both wt and Mdr1
0/0 mouse brains
(Figure 2). We found a ,100-fold difference in the brain
quinacrine concentration between wt and Mdr1
0/0 mice
(Figure 2). In wt mice, quinacrine and its metabolites (M1 and
M2) were rapidly cleared from brain by 7 d after the cessation of
treatment; in contrast, quinacrine remained elevated in the brains
of Mdr1
0/0 mice for up to 21 d after ceasing treatment (Figure 3).
Notably, ,1 mM brain quinacrine was found at the end of
treatment phase in wt mice and 21 d after treatment ceased in
Mdr1
0/0 mice (Figure 3). The concentrations of M1 for wt mouse
brains were under the detection limit.
Quinacrine Distribution in Mouse Brain
Having established that quinacrine accumulates and can
persist for weeks in the CNS of Mdr1
0/0 mice, we examined its
brain distribution using fluorescence microscopy. Mdr1
0/0 mice
were treated either orally with 40 mg/kg/day of quinacrine for
25 d or by IV tail injection with 20 mg/kg of quinacrine for
1 h. The distribution of quinacrine in brain sections was
visualized by imaging its intrinsic fluorescence. Quinacrine was
clearly detectable in various regions of both orally treated and
IV tail-injected Mdr1
0/0 mouse brains, but not in untreated and
PBS-treated Mdr1
0/0 brains (Figure 4B and 4C). Although
quinacrine was distributed throughout the brain, we observed
differential distribution across brain regions. In the hippocam-
pus, quinacrine fluorescence was intense in granule cell nuclei of
the dentate gyrus (Figure 4A). In the cerebellum, nuclear
staining was observed in neurons and glia of the granule,
Purkinje, and molecular cell layers, but little or no quinacrine
fluorescence was seen in the white matter (Figure 4A and 5).
The quinacrine signal was intense in nerve cell bodies of the
cerebral cortex, thalamus, and brainstem (Figure 4A).
In order to rule out the possibility of artificial localization of
quinacrine due to the compositional changes in membranes
resulting from the deletion of mdr genes, we also examined
quinacrine distribution in the brains of wt mice. Although the
quinacrine fluorescence signal was not detectable in the brains of
wt mice treated orally with 40 mg/kg/day of quinacrine for 25 d,
it was measurable when wt mice were injected with 20 mg/kg of
quinacrine by IV tail-injection. At 1 h after IV tail injection, the
P-gp-Mediated Efflux of Quinacrine in Mouse Brain
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0/0 were similar
(Figure 5). Notably, quinacrine signals were faint in the brains of
wt mice collected at 3 h after IV injection (data not shown). By
24 h after IV injection, quinacrine signals were absent in the
brains of wt mice but remained intense in Mdr1
0/0 mice
(Figure 5). These observations argue that wt and Mdr1
0/0 mice
accumulate quinacrine in similar regions of the brain, but at
different concentrations.
P-gp Inhibitors Increased Quinacrine in Brains of Wild-
type Mice
In order to be useful clinically, quinacrine levels in the brain
must remain high, which can be achieved by co-administration of
a P-gp inhibitor. We attempted to increase quinacrine levels in the
brains of wt mice by utilizing four known P-gp inhibitors:
quinidine, CyA, verapamil, and disulfiram. Groups of wt mice
were treated with 100 mg/kg of the P-gp inhibitor for 1 h
(Figure 6A) or 2 h (Figure 6B) prior to quinacrine dosing by
oral gavage. Tissues were then collected 6 or 24 h after quinacrine
administration.
Wild-type mice treated with 100 mg/kg of CyA prior to
quinacrine showed a 6-fold increase in brain concentrations of
quinacrine compared to controls (Figure 6A), which was ,70%
of the concentration measured in the brains of P-gp–ablated
Mdr1
0/0 mice after 6 h of quinacrine treatment (Figure 6A).
Quinacrine levels in CyA-treated mice only increased ,3-fold
when quinacrine was administered 2 h after CyA (Figure 6B) or
when brain tissue was collected at 24 h post–quinacrine admin-
istration. Quinidine increased quinacrine in a similar pattern, but
to a lesser extent (Figure 6). In contrast, quinacrine brain
concentrations were higher in the brains of wt mice receiving the
P-gp inhibitor verapamil at 24 h compared to 6 h (Figure 6).
Also, lengthening the interval between verapamil and quinacrine
administration to 2 h resulted in higher quinacrine concentrations
Figure 4. Distribution of quinacrine in the brains of Mdr1
0/0
mice by fluorescence microscopy. Mdr1
0/0 mice were treated with
20 mg/kg/day of quinacrine via IV tail-injection and euthanized after
1h( A) and 3 h (B). In mice after 1 h, a high level of quinacrine
fluorescence was seen in the nuclei of the cerebellum (CB) and
hippocampus (HIP) as well as in the nerve cell bodies of the brainstem
(BS), thalamus (THAL), and cortex (CTX). GC, granule cell layer; WM,
white matter tract; DG, dentate gyrus; arrowheads, cell bodies of
neurons or astrocytes. (B) In mice after 3 h, a high level of quinacrine
fluorescence was observed only in the brainstem of quinacrine-treated
mice (left) but not in the brainstem of PBS-treated mice (right). (C) Mice
were treated with 40 mg/kg/day of quinacrine in a chocolate-flavored
liquid diet for 25 days. A high level of quinacrine fluorescence was
observed in the brainstem of quinacrine-treated mice (left), which was
not observed in the brainstem of untreated mice (right). Scale bar in A
represents 50 mm and applies to all images.
doi:10.1371/journal.pone.0039112.g004
Figure 5. Distribution of quinacrine in the brains of Mdr1
0/0 and wt mice by fluorescence microscopy. Mice were treated with 20 mg/kg
of quinacrine via IV tail-injection and euthanized after 1 h or 24 h. Brains with the highest signals for both wt and Mdr1
0/0 mice were chosen to get
the best quality images, taken at 406. At 1 h, quinacrine fluorescence was strong in both Mdr1
0/0 and wt mice. At 24 h, quinacrine fluorescence was
observed only in Mdr1
0/0 mice; only lipofuscin autofluorescence in Purkinje cells was observed in wt mice. Scale bar represents 50 mm and applies to
all panels. GC, granule cell layer; P, Purkinje cell layer; ML, molecular cell layer.
doi:10.1371/journal.pone.0039112.g005
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different P-gp inhibitors may enable sustained increases in brain
quinacrine levels. At 50 mg/kg doses, the P-gp inhibitors did not
influence the quinacrine concentration in wt brain tissue (data not
shown).
Discussion
P-gp is a transmembrane glycoprotein that functions as an
adenosine triphosphatase energy-dependent transporter. The BBB
prevents many foreign substances, such as proteins, peptides, and
most drugs, from gaining access to the CNS. P-gp is expressed in
the endothelial cells of the BBB and functions as an active drug
efflux pump. The P-gp pump keeps the concentrations of a wide
variety of foreign substances low and thereby provides an
important protective barrier against many potentially toxic
molecules. P-gp also removes many drugs from the CNS [21,24]
and thus reduces their potential effectiveness [22]. This being the
case, inhibition of P-gp may be required to increase the
bioavailability of drugs targeting CNS diseases.
In a recent study, the utility of quinacrine in combination with a
c-secretase inhibitor cleared PrP
Sc from the brains of scrapie-
infected mice [25]. Unfortunately, the survival of the scrapie-
infected mice could not be prolonged due to toxicity of the c-
secretase inhibitor. Quinacrine also proved ineffective in mouse
models of glioblastoma and heat-induced injury [12,13].
In our study, P-gp inhibitors given prior to quinacrine
administration increased the concentration of the drug up to 6-
fold in wt mouse brain (Figure 6). Although we have shown that
inhibition of P-gp with CyA enhanced bioavailability of quinacrine
in the brain, it is likely that the administration protocol is
suboptimal to achieve maximal and sustained quinacrine concen-
trations in the brain for prolonged periods. Quinacrine was
cleared from the CNS in several hours when it was administered
with a P-gp inhibitor in wt mice. This observation suggests that
higher or frequent doses of quinacrine with a P-gp inhibitor may
need to be given. In our study, CyA seemed to be a fast-acting
inhibitor while verapamil was a slow-acting inhibitor: quinacrine
concentrations were highest at 6 h with CyA and at 24 h with
verapamil (Figure 6). In future studies, it might be interesting to
examine combinations of P-gp inhibitors.
Since its synthesis in 1931, quinacrine has been widely used for
treatment and prevention of malaria and chronic inflammatory
conditions [8]. The mechanisms of action of quinacrine remain
unclear but many recent studies have suggested that it might be
useful in treating cancer and neurodegenerative diseases. In
addition to its ability to intercalate into DNA, quinacrine has been
reported to regulate transcription factors, including NF-kB, hsp70
and p53 [12,27,28], which control immune responses, prolifera-
tion, and tumor genesis. Another study suggested that quinacrine
protects heat-induced neuronal injury via inhibition of cPLA2
[13]. Interestingly, a multimeric quinacrine conjugate has been
reported to inhibit Ab-amyloid fibril formation [29].
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